Table A7.
Data Integration Matrix
| Product Name (generic) | Index Score | Index Rank by Score | Adjusted Index Rank | NNT | Cost per Event Avoided or Patient Benefiting ($ in thousands) | NNT Cost Model Rank | Cost per Average Month Gained ($ in thousands) | Outcome of Record | Cost Model Rank | Final Rank |
|---|---|---|---|---|---|---|---|---|---|---|
| Tier 1 | ||||||||||
| Curalib (A) | 27 | NA | NA | 14.3 | 321.75 | NA | 4.5 | R | NA | |
| Tier 2 | ||||||||||
| Pallalib (B) | 25 | 1 | 2 | 8.5 | 400.80 | 1 | 6.0 | P | 1 | |
| Oxymoralib (C) | 24 | 2 | 1 | 12.3 | 821.70 | 2 | 24.75 | P | 2 |
NOTE. The matrix displays relevant data in a single field. In tier 2, B ranks better than C by scoring index alone, but receives a lower adjusted rank after considering other factors (see Table A3). Both costing models favor B over C. Depending on the social, economic, and political context in which they operate, decision makers could still favor C. The module illustrates the tool's function in focusing on data without restricting flexibility in judgments. The main gain is in transparency.
Abbreviations: NNT, number needed to treat; NA, not available; R, recurrence-free survival; P, progression-free survival.